| 8.49 -0.18 (-2.08%) | 04-21 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 11.27 | 1-year : | 12.77 |
| Resists | First : | 9.65 | Second : | 10.93 |
| Pivot price | 8.31  |
|||
| Supports | First : | 7.57 | Second : | 6.29 |
| MAs | MA(5) : | 8.66 |
MA(20) : | 8.44 |
| MA(100) : | 8.38 |
MA(250) : | 7.87 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 77.2 |
D(3) : | 74.1 |
| RSI | RSI(14): 45.9 |
|||
| 52-week | High : | 11.97 | Low : | 5.8 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ NVAX ] has closed below upper band by 36.4%. Bollinger Bands are 33.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 8.75 - 8.81 | 8.81 - 8.84 |
| Low: | 8.28 - 8.35 | 8.35 - 8.4 |
| Close: | 8.4 - 8.5 | 8.5 - 8.57 |
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Fri, 17 Apr 2026
Novavax (NVAX) Outperforms Broader Market: What You Need to Know - Yahoo Finance
Wed, 08 Apr 2026
Assessing Novavax (NVAX) Valuation After Renewed Focus On Covid And Malaria Vaccine Deals - Yahoo Finance
Mon, 30 Mar 2026
Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know - Yahoo Finance
Tue, 17 Mar 2026
Here is What to Know Beyond Why Novavax, Inc. (NVAX) is a Trending Stock - Yahoo Finance
Tue, 03 Mar 2026
Is Trending Stock Novavax, Inc. (NVAX) a Buy Now? - Yahoo Finance
Thu, 26 Feb 2026
Why Is Novavax (NVAX) Stock Soaring Today - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 163 (M) |
| Shares Float | 140 (M) |
| Held by Insiders | 4.9 (%) |
| Held by Institutions | 69.6 (%) |
| Shares Short | 44,990 (K) |
| Shares Short P.Month | 50,920 (K) |
| EPS | 2.57 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.8 |
| Profit Margin | 39.1 % |
| Operating Margin | 14.2 % |
| Return on Assets (ttm) | 25.7 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 66.5 % |
| Gross Profit (p.s.) | 4.37 |
| Sales Per Share | 6.87 |
| EBITDA (p.s.) | 3.62 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -245 (M) |
| Levered Free Cash Flow | -332 (M) |
| PE Ratio | 3.29 |
| PEG Ratio | 1.3 |
| Price to Book value | -10.75 |
| Price to Sales | 1.23 |
| Price to Cash Flow | -5.66 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|